OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Khalil on the Use of Nivolumab/Ipilimumab Combination in NSCLC

March 24th 2023

Maya Khalil, MD, discusses key clinical trial updates on the use of nivolumab and ipilimumab with or without chemotherapy in non–small cell lung cancer.

Dr Zonder on the Expansion of Targeted Therapies in R/R Multiple Myeloma

March 24th 2023

Jeffery Zonder, MD, discusses the need for expanding the armamentarium of targeted therapies for patients with relapsed/refractory multiple myeloma.

Dr Zonder on CAR T-cell Therapy Vs Bispecific Antibodies in Relapsed/Refractory Myeloma

March 23rd 2023

Jeffery Zonder, MD, discusses the process of choosing between CAR T-cell therapy and bispecific antibody approaches for the treatment of patients with relapsed/refractory multiple myeloma.

Dr Brahmer on First-line Tremelimumab/Durvalumab Plus Chemotherapy in NSCLC

March 23rd 2023

Julie Renee Brahmer, MD, discusses the use of tremelimumab plus durvalumab and platinum-based chemotherapy for the first-line treatment of patients with non–small cell lung cancer, and how decisions can be made between this regimen and nivolumab plus ipilimumab and chemotherapy.

Dr Mitzman on the Emergence of Immunotherapy in Early-Stage NSCLC

March 23rd 2023

Brian Mitzman, MD, FACS, FCCP, discusses the emergence of immunotherapy as a treatment option for patients with early-stage non–small cell lung cancer.

Dr Christensen on Azacitidine Plus Venetoclax in AML

March 23rd 2023

Bradley W. Christensen, MD, discusses findings from the phase 3 VIALE-A trial in patients with acute myeloid leukemia.

Dr. Chiang on Advancements in the Treatment and Characterization of SCLC

March 23rd 2023

Anne Chiang, MD, PhD, discusses recent advancements in the biological understanding and treatment of small cell lung cancer.

Dr. Roque on the Importance of Biomarker Testing in Advanced Endometrial Cancer

March 23rd 2023

Dario R. Roque, MD, discusses how biomarker testing can lead to more accurate and effective treatment selection in advanced endometrial cancer.

Dr Callander on Early CAR T-cell Therapy Referrals in Multiple Myeloma

March 23rd 2023

Natalie S. Callander, MD, discusses the potential benefits of referring patients with multiple myeloma to CAR T-cell therapy earlier in their disease course.

Dr Henick on Biomarker Detection in Lung Cancer

March 22nd 2023

Brian Henick, MD, discusses the different ways to identify biomarkers of immunotherapy response in patients with lung cancer and how refining these approaches may improve individualized treatment approaches in the future.

Dr Deol on the Current Limitations of CAR T-cell Therapy in R/R Myeloma

March 22nd 2023

Abhinav Deol, MD, discusses the current limitations of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Bachanova on NK Cell Therapy in NHL

March 22nd 2023

Veronika Bachanova, MD, PhD, discusses findings from a spatial analysis of the tumor microenvironment in patients with non-Hodgkin lymphoma who received and responded to adoptive natural killer cell therapy.

Dr Stadler on Enhancing Diversity in Early Phase Clinical Trials For Underserved Communities

March 22nd 2023

Walter M. Stadler, MD, discusses his role within the Stand Up To Cancer® 4-team initiative, where he will aim to enhance diversity in early-phase clinical trials in underserved urban community.

Dr Domchek on the Importance of Germline Testing in Breast Cancer Care

March 22nd 2023

Susan Domchek, MD, FASCO, discusses the importance of germline testing in breast cancer care.

Dr Dreicer on the Potential Role of Triplet Therapy in De Novo Metastatic Prostate Cancer

March 22nd 2023

Robert Dreicer, MD, discusses the use of triplet therapy in the first-line management of de novo metastatic prostate cancer.

Dr Cummings on the Investigation of Osimertinib in EGFR-Mutant NSCLC

March 22nd 2023

Amy L. Cummings, MD, discusses the significance of the phase 3 FLAURA trial evaluating osimertinib in locally advanced or metastatic non–small cell lung cancer (NSCLC).

Dr. Godara on Approved CAR T-cell Therapies in Multiple Myeloma

March 21st 2023

Amandeep Godara, MBBS, discusses CAR T-cell therapies currently available for patients with multiple myeloma.

Dr. Wang on the Treatment Options for Unfit Patients With AML

March 21st 2023

Eunice Wang, MD, discusses treatment options in unfit patients with acute myeloid leukemia.

Dr. Chao on Key Trials Leading to FDA Approvals in Metastatic NSCLC

March 21st 2023

Yvonne Chao, MD, PhD, discusses key trials leading to FDA approvals in metastatic non–small cell lung cancer.

Dr. O'Regan on the RIGHT Choice Trial in HR+/HER2- Breast Cancer

March 21st 2023

Ruth M. O’Regan, MD, discusses how results from the phase 2 RIGHT Choice trial could influence the treatment paradigm in hormone receptor–positive, HER2-negative breast cancer.